199 related articles for article (PubMed ID: 29328653)
1. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
[TBL] [Abstract][Full Text] [Related]
2. High hydrostatic pressure encapsulation of doxorubicin in ferritin nanocages with enhanced efficiency.
Wang Q; Zhang C; Liu L; Li Z; Guo F; Li X; Luo J; Zhao D; Liu Y; Su Z
J Biotechnol; 2017 Jul; 254():34-42. PubMed ID: 28591619
[TBL] [Abstract][Full Text] [Related]
3. Genetically Encoding Albumin Binding into Chemotherapeutic-loaded Polypeptide Nanoparticles Enhances Their Antitumor Efficacy.
Yousefpour P; McDaniel JR; Prasad V; Ahn L; Li X; Subrahmanyan R; Weitzhandler I; Suter S; Chilkoti A
Nano Lett; 2018 Dec; 18(12):7784-7793. PubMed ID: 30461287
[TBL] [Abstract][Full Text] [Related]
4. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
[TBL] [Abstract][Full Text] [Related]
5. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
6. Albumin-binding domain extends half-life of glucagon-like peptide-1.
Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
[TBL] [Abstract][Full Text] [Related]
7. Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements.
Falvo E; Tremante E; Arcovito A; Papi M; Elad N; Boffi A; Morea V; Conti G; Toffoli G; Fracasso G; Giacomini P; Ceci P
Biomacromolecules; 2016 Feb; 17(2):514-22. PubMed ID: 26686226
[TBL] [Abstract][Full Text] [Related]
8. Integrin α
Huang CW; Chuang CP; Chen YJ; Wang HY; Lin JJ; Huang CY; Wei KC; Huang FT
J Nanobiotechnology; 2021 Jun; 19(1):180. PubMed ID: 34120610
[TBL] [Abstract][Full Text] [Related]
9. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
[TBL] [Abstract][Full Text] [Related]
10. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
[TBL] [Abstract][Full Text] [Related]
11. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin.
Yousefpour P; Ahn L; Tewksbury J; Saha S; Costa SA; Bellucci JJ; Li X; Chilkoti A
Small; 2019 Mar; 15(12):e1804452. PubMed ID: 30756483
[TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
[TBL] [Abstract][Full Text] [Related]
13. Mechanism Study of Thermally Induced Anti-Tumor Drug Loading to Engineered Human Heavy-Chain Ferritin Nanocages Aided by Computational Analysis.
Yin S; Liu Y; Dai S; Zhang B; Qu Y; Zhang Y; Choe WS; Bi J
Biosensors (Basel); 2021 Nov; 11(11):. PubMed ID: 34821660
[TBL] [Abstract][Full Text] [Related]
14. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
Ren Z; Zhao J; Cao X; Wang F
Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
[TBL] [Abstract][Full Text] [Related]
15. Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting.
Jiang B; Jia X; Ji T; Zhou M; He J; Wang K; Tian J; Yan X; Fan K
Sci China Life Sci; 2022 Feb; 65(2):328-340. PubMed ID: 34482518
[TBL] [Abstract][Full Text] [Related]
16. Heat sensitive E-helix cut ferritin nanocages for facile and high-efficiency loading of doxorubicin.
Xia H; Xu H; Wang J; Wang C; Chen R; Tao T; Xu S; Zhang J; Ma K; Wang J
Int J Biol Macromol; 2023 Dec; 253(Pt 3):126973. PubMed ID: 37729988
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of a long-acting ciliary neurotrophic factor via genetically fused with an albumin-binding domain.
Xu L; Zhang C; Liu L; Zhang Y; Wang Q; Wang J; Liu Y; Su Z
Protein Expr Purif; 2017 Nov; 139():14-20. PubMed ID: 28711730
[TBL] [Abstract][Full Text] [Related]
18. TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer.
Cheng X; Fan K; Wang L; Ying X; Sanders AJ; Guo T; Xing X; Zhou M; Du H; Hu Y; Ding H; Li Z; Wen X; Jiang W; Yan X; Ji J
Cell Death Dis; 2020 Feb; 11(2):92. PubMed ID: 32024821
[TBL] [Abstract][Full Text] [Related]
19. H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection.
Liang M; Fan K; Zhou M; Duan D; Zheng J; Yang D; Feng J; Yan X
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14900-5. PubMed ID: 25267615
[TBL] [Abstract][Full Text] [Related]
20. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
